A method to accurately inject tumor cells into the caudate/putamen nuclei of the mouse brain

Tokai Journal of Experimental and Clinical Medicine

Volumn 29, Issue 4, 2004, Pages 167-173

  Yamada, Shinya ^a   Khankaldyyan, Vazgen ^b   Bu, Xiang ^b   Suzuki, Atsushi ^b   Gonzalez Gomez, Ignacio ^b   Takahashi, Kouichi ^b   McComb, J Gordon ^b   Laug, Walter E ^b  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Brain tumor model; Nude mice; Xenograft

Indexed keywords

INDIGO CARMINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN VENTRICLE; CANCER GRAFT; CAUDATE NUCLEUS; CELL VIABILITY; GLIOMA CELL; INJECTION SITE; MOUSE; NONHUMAN; PARAMETER; PUTAMEN; REPRODUCIBILITY; STEREOTAXIC SURGERY; SUBARACHNOID SPACE; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CAUDATE NUCLEUS; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; GLIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PUTAMEN; REPRODUCIBILITY OF RESULTS; STEREOTAXIC TECHNIQUES; TIME FACTORS; TUMOR BURDEN;

EID: 13444267514     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andreansky S, Soroceanu L, Flotte ER, et al: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502-1509, 1997.
2. Brem S, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972.
3. Cserr HF: Relationship between cerebrospinal fluid and interstitial fluid of brain. Fed Proc 33: 2075-2078, 1974.
4. Cserr HF, Ostrach LH: Bulk flow of interstitial fluid after intracranial injection of blue dextran 2000. Exp Neurol 45: 50-60, 1974.
5. Engebraaten O, Hjortland GO, Juell S, et al: Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97: 846-852, 2002.
6. Epstein AL, Herman MM, Kim H, et al: Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse. Cancer 37: 2158-2176, 1976.
7. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972.
8. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
9. Folkman J, Merler E, Abernathy C, et al: Isolation of a tumor factor responsible or angiogenesis. J Exp Med 133: 275-288, 1971.
10. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857, 1995.
11. Friedman HS, Keir ST, Houghton PJ, et al: Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48: 413-416, 2001.
12. Friedman HS, Schold SC, Jr., Varia M, et al: Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Cancer Res 43: 3088-3093, 1983.
13. Kaye AH, Morstyn G, Gardner I, et al: Development of a xenograft glioma model in mouse brain. Cancer Res 46: 1367-1373, 1986.
14. Keir ST, Hausheer F, Lawless AA, et al: Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48: 83-87, 2001.
15. Kirsch M, Strasser J, Allende R, et al: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58: 4654-4659, 1998.
16. Lal S, Lacroix M, Tofilon P, et al: An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 92: 326-333, 2000.
17. Liang SC, Lin SZ, Yu JF, et al: F344-rnu/rnu athymic rats: breeding performance and acceptance of subcutaneous and intracranial xenografts at different ages. Lab Anim Sci 47: 549-553, 1997.
18. MacDonald TJ, Tabrizi P, Shimada H, et al: Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein. Neurosurgery 43: 1437-1442; discussion 1442-1433, 1998.
19. McCutcheon IE, Friend KE, Gerdes TM, et al: Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg 92: 306-314, 2000.
20. Mishima K, Johns TG, Luwor RB, et al: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61: 5349-5354, 2001.
21. Mishima K, Mazar AP, Gown A, et al: A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 97: 8484-8489, 2000.
22. Noll EN, Lin J, Nakatsuji Y, et al: GM3 as a novel growth regulator for human gliomas. Exp Neurol 168: 300-309, 2001.
23. Pollack IF, Erff M, Bom D, et al: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59: 4898-4905, 1999.
24. Teicher BA, Alvarez E, Mendelsohn LG, et al: Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy. Adv Enzyme Regul 39: 313-327, 1999.
25. Ullrich N, Bordey A, Gillespie GY, et al: Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience 83: 1161-1173, 1998.
26. Wang S, Khan A, Lang FF, et al: Conditional gene expression in human intracranial xenograft tumors. Biotechniques 31: 196-202, 2001.
27. Williams JA, Yuan X, Dillehay LE, et al: Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Int J Radiat Oncol Biol Phys 42: 631-639, 1998.
28. Yamada S, DePasquale M, Patlak CS, et al: Albumin outflow into deep cervical lymph from different regions of rabbit brain. American Journal of Physiology 261: H1197-1204, 1991.